Instalab
Mounjaro · tirzepatide · once-weekly injection · for type 2 diabetes

Two receptors. One injection a week. Biggest A1C drop in the class.

The once-weekly dual GIP/GLP-1 for type 2 diabetes. In SURPASS, Mounjaro® (tirzepatide) outperformed semaglutide and titrated insulin glargine on A1C. Prescription, titration, and physician follow-up included.

~2.5%A1C reduction at top dose (SURPASS-1)
6 doses2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg
2 formsAutoinjector or vial
Mounjaro Prescription Review
Mounjaro · vial or single-dose autoinjector · once weekly
Licensed US physician review
12,000+ patients treated
Available in all 50 states
Ongoing titration and follow-up
How it works

From questionnaire to first injection.

No clinic visits. A licensed physician picks the right form and starting dose, manages every titration step, and routes you to the most affordable supply.

Step 1

2-minute questionnaire

Tell us about your A1C, diabetes history, prior GLP-1 use, BMI, and any related conditions.

Step 2

Physician review

A licensed physician confirms eligibility, picks vial or autoinjector, screens for contraindications, and writes your starting prescription. Usually within 1 business day.

Step 3

Cost check and dispensing

We verify insurance and file prior authorization. If self-pay makes more sense, we shop across manufacturer-direct and pharmacy options for whichever form you prefer and show you the lowest monthly cost before you commit.

Step 4

Titration and follow-up

Start at 2.5mg weekly and step up every 4 weeks toward your maintenance dose. We monitor side effects, manage refills, and time each dose increase with you.

Pricing

What you'll actually pay.

Two line items: Instalab Membership and the Mounjaro medication itself, billed by the pharmacy or by Lilly directly.

Instalab Membership

Physician oversight, titration management, A1C and metabolic follow-up

$—/mo

Mounjaro

Tirzepatide injection, billed by pharmacy or by Lilly directly

Cash price$499–532/monthManufacturer-direct vials, 2.5–15mg
With insurance$25–100/monthTypical copay for pens, if covered

Why pay a membership fee? Mounjaro needs a physician who actively manages titration, side effects, and form selection across six dose strengths. Membership covers the visits, renewals, prior authorization, and shopping your dose across manufacturer-direct and pharmacy options so you land on the cheapest source for the form you want. Labs are billed separately.

Will my insurance cover Mounjaro?

Most commercial and Medicare plans cover Mounjaro for type 2 diabetes, often with prior authorization confirming the diagnosis. Copays are typically $25 to $100 per month with coverage. We file the prior authorization. If insurance won't cover it, we shop self-pay options across manufacturer-direct and pharmacy channels for whichever form you prefer.

Why membership

Mounjaro works. Titration and follow-up take ongoing care.

It needs a physician who manages dose increases, side effects, and metabolic monitoring across six dose steps. Here's how our team handles that for you.

  1. Week 1Day 1–5

    Physician evaluation and prescription

    A licensed physician reviews your diabetes history, A1C, and goals, then writes your starting prescription at 2.5mg. We verify insurance and file prior authorization in parallel.

  2. Week 2

    First injection at home

    Your Mounjaro vial or autoinjector ships from the pharmacy. We walk you through self-injection and check in after your first dose.

  3. Week 4+

    Titration every 4 weeks

    Step up by 2.5mg every 4 weeks if tolerated. Maintenance doses are 5, 10, or 15mg depending on A1C target and tolerability.

  4. Month 3+

    A1C recheck and ongoing care

    Recheck A1C at month 3. Your physician tracks A1C, weight, and labs over time.

Without membership

Schedule a PCP or endocrinology visit. Wait months. Hope they know how to titrate. Chase prior auth and manufacturer paperwork yourself.

With Instalab

2-minute questionnaire. Physician review within 1 business day. Insurance and manufacturer-direct supply handled. Titration and side-effect check-ins built in.

About the medication

One injection a week. Two ways to take it.

Mounjaro comes as a single-dose autoinjector or a vial. Same medicine, two formats — pick the one that fits your routine and budget. Both are subcutaneous injections once a week, into the thigh, stomach, or upper arm.

  • Two forms, same medicineVials are drawn with a syringe and usually carry the lowest cash price. Single-dose autoinjectors are one click-and-hold injection. We shop manufacturer-direct and pharmacy options for whichever form you choose.
  • Once weekly, any dayPick a weekday and stick with it. Inject any time of day, with or without food.
  • Slow, steady titrationStart at 2.5mg for the first 4 weeks (this dose is for titration, not maintenance). Step up by 2.5mg every 4 weeks toward maintenance.
  • Ongoing physician supportYour care team is a message away for nausea, dose timing, and metabolic monitoring across the plan.
Why Mounjaro

Dual incretin agonism. Largest A1C drops in the class.

Mounjaro is tirzepatide, the same molecule as Zepbound but with the FDA-approved indication for type 2 diabetes rather than chronic weight management. Tirzepatide activates both the GIP and GLP-1 receptors. Across the SURPASS trials, it produced larger A1C reductions than semaglutide (1mg) and titrated insulin glargine. Weight loss accompanies the A1C drop and is substantial, though Mounjaro is not FDA-approved as a weight-loss medication on its own.

  • A1C drops up to ~2.5% at the top doseIn SURPASS-1, drug-naive adults with T2D on Mounjaro 15mg dropped A1C by a mean ~2.0 to 2.5% over 40 weeks. In head-to-head trials, tirzepatide outperformed semaglutide 1mg on A1C and weight.
  • A dual incretin mechanismActivating both GIP and GLP-1 receptors slows gastric emptying, reduces appetite, and improves insulin sensitivity more than activating either receptor alone.
  • Substantial weight loss as a side benefitEven at T2D doses, patients commonly lose 8 to 15% of body weight. For weight loss specifically, tirzepatide is approved as Zepbound at the same doses with a weight-management indication.

The SURPASS trials

The SURPASS program was a series of randomized trials comparing tirzepatide to placebo, semaglutide, and titrated insulin in adults with type 2 diabetes. Across these trials, tirzepatide produced larger A1C reductions and more weight loss than the comparators. SURPASS-1 (drug-naive) showed A1C drops of ~2.0 to 2.5%; SURPASS-2 directly compared tirzepatide to semaglutide 1mg, with tirzepatide producing larger A1C and weight reductions. SURPASS-CVOT, the CV outcomes trial, is ongoing.

~2.0–2.5%
Mean A1C reduction at top dose
8–15%
Typical weight loss range
40 wks
Pivotal trial duration

Mounjaro is a prescription medicine. Important safety information applies. The most common side effects are gastrointestinal, usually mild during titration. There is a boxed warning for thyroid C-cell tumors, based on rodent studies.

Ready when you are

Lower A1C with the dual incretin.

Answer the questionnaire. A physician reviews your case and, if Mounjaro is appropriate, prescribes it. We handle titration, refills, and follow-up.

No commitment to treatment. Mounjaro is for type 2 diabetes.